The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP).
Drug Testing and Analysis December 1, 2024 DOI: 10.1002/dta.3667 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Historical analysis Peer reviewed |
|---|---|
| Keywords | Owsley Shulgin Psychotomimetic Drug history Psychedelic history Dom history Drug origins 1967 drugs Drug impact Drug policy Public health Societal impact Drug crisis response Molecular neuroscience Psychedelic chemistry Psychopharmacology Drug development Compound research Drug controversy Drug risks Ethical issues Notorious drugs Controversial past |
| Citations | 5 |
| Key points | Argues that Alexander Shulgin played a poorly understood role in providing DOM to Owsley Stanley for public distribution in 1967, and that mistaken warnings about combining DOM with chlorpromazine led to better non-pharmacological drug crisis response. |
Abstract
The story of the 1967 appearance of the powerful psychedelic 2,5-dimethoxy-4-methylamphetamine (DOM, STP) commonly omits details and often includes hyperbole and inaccuracies. It is well known how and when the drug was first distributed to the public for free by Owsley Stanley, but the role that Alexander Shulgin played in providing that material is not as well understood. In the interest of transparency and historical accuracy, this article attempts to present an accurate account of this well-known but inadequately detailed event. It follows DOM's development as an experimental substance believed to hold potential promise in psychotherapeutic applications through its appearance as a street drug generating bad press and a lasting bad impression among the public. One of the more interesting questions is why Shulgin would have taken such an immense risk in releasing this material to clandestine operators. While DOM was still legal it was also Dow's intellectual property, so discovery of his involvement could have jeopardized his career. The escape is especially curious as all fingers would logically first point towards Shulgin as the source. Drawing from published and unpublished sources, the authors attempt to suggest answers. DOM rapidly faded into oblivion before human pharmacodynamics and pharmacokinetics could be established. In this account, the reader is informed of the potential value that the compound played in non-clinical molecular neuroscience, elucidating receptor specificity of new drugs, and how mistaken warnings about combining DOM with chlorpromazine led to better non-pharmacological drug crisis response.
Citations in the library
Cited by 4
- 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review. ACS Pharmacology & Translational Science June 14, 2024
- The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors. Molecular Pharmacology 2026
- The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States Journal of Psychoactive Drugs October 9, 2025
- Interactions between fentanyl and 2,5-dimethoxy-4-methylamphetamine: Ventilatory effects in nonhuman primates. Journal of Pharmacology and Experimental Therapeutics October 1, 2025
Cites 14
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- 2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug Science November 3, 1967
- DOM (STP), a New Hallucinogenic Drug, and DOET: Effects in Normal Subjects American Journal of Psychiatry September 1, 1968
- Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore. ACS Pharmacology & Translational Science April 9, 2021
- Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus. Pharmacology, Biochemistry, and Behavior February 1, 1998
and 9 more in the library